Early changes in renal resistive index and mortality in diabetic and nondiabetic kidney transplant recipients: a cohort study.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
19 02 2021
Historique:
received: 27 11 2020
accepted: 02 02 2021
entrez: 20 2 2021
pubmed: 21 2 2021
medline: 15 12 2021
Statut: epublish

Résumé

Renal resistive index (RI) predicts mortality in renal transplant recipients (RTR). However, its predictive value may be different according to the time of measurement. We analysed RI changes between 1 month and 3 months after transplantation and its predictive value for death with a functioning graft (DWFG). We conducted a retrospective study in 1685 RTR between 1985 and 2017. The long-term predictive value of changes in RI value from 1 month to 3 months was assessed in diabetic and non-diabetic RTR. Best survival was observed in RTR with RI < 0.70 both at 1 and 3 months, and the worst survival was found in RTR with RI ≥ 0.70 both at 1 and 3 months (HR = 3.77, [2.71-5.24], p < 0.001). The risk of DWFG was intermediate when RI was < 0.70 at 1 month and ≥ 0.70 at 3 months (HR = 2.15 [1.29-3.60], p = 0.003) and when RI was ≥0.70 at 1 month and < 0.70 at 3 months (HR = 1.90 [1.20-3.03], p = 0.006). In diabetic RTR, RI was significantly associated with an increased risk of death only in those with RI < 0.70 at 1 month and ≥ 0.70 at 3 months (HR = 4.69 [1.07-20.52], p = 0.040). RI considered as a continuous variable at 1 and 3 months was significantly associated with the risk of DWFG in nondiabetic but not in diabetic RTR. RI changes overtime and this impacts differently diabetic and nondiabetic RTR. RI short-term changes have a strong prognosis value and refines the risk of DWFG associated with RI.

Sections du résumé

BACKGROUND
Renal resistive index (RI) predicts mortality in renal transplant recipients (RTR). However, its predictive value may be different according to the time of measurement. We analysed RI changes between 1 month and 3 months after transplantation and its predictive value for death with a functioning graft (DWFG).
METHODS
We conducted a retrospective study in 1685 RTR between 1985 and 2017. The long-term predictive value of changes in RI value from 1 month to 3 months was assessed in diabetic and non-diabetic RTR.
RESULTS
Best survival was observed in RTR with RI < 0.70 both at 1 and 3 months, and the worst survival was found in RTR with RI ≥ 0.70 both at 1 and 3 months (HR = 3.77, [2.71-5.24], p < 0.001). The risk of DWFG was intermediate when RI was < 0.70 at 1 month and ≥ 0.70 at 3 months (HR = 2.15 [1.29-3.60], p = 0.003) and when RI was ≥0.70 at 1 month and < 0.70 at 3 months (HR = 1.90 [1.20-3.03], p = 0.006). In diabetic RTR, RI was significantly associated with an increased risk of death only in those with RI < 0.70 at 1 month and ≥ 0.70 at 3 months (HR = 4.69 [1.07-20.52], p = 0.040). RI considered as a continuous variable at 1 and 3 months was significantly associated with the risk of DWFG in nondiabetic but not in diabetic RTR.
CONCLUSION
RI changes overtime and this impacts differently diabetic and nondiabetic RTR. RI short-term changes have a strong prognosis value and refines the risk of DWFG associated with RI.

Identifiants

pubmed: 33607945
doi: 10.1186/s12882-021-02263-8
pii: 10.1186/s12882-021-02263-8
pmc: PMC7893742
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

62

Références

Nephrol Dial Transplant. 2012 Oct;27(10):3958-63
pubmed: 22247231
Comput Math Methods Med. 2013;2013:745742
pubmed: 24454541
AJR Am J Roentgenol. 2003 Apr;180(4):885-92
pubmed: 12646425
Clin J Am Soc Nephrol. 2010 Oct;5(10):1867-72
pubmed: 20616164
Rev Prat. 1975 Dec 21;25(59):4671-80
pubmed: 1215793
Diabetologia. 1998 Jan;41(1):121-4
pubmed: 9498641
J Clin Hypertens (Greenwich). 2019 Mar;21(3):382-389
pubmed: 30767377
Transplant Proc. 2006 Jan-Feb;38(1):42-5
pubmed: 16504659
N Engl J Med. 2003 Jul 10;349(2):115-24
pubmed: 12853584
Nephrol Dial Transplant. 2012 Mar;27(3):1225-31
pubmed: 21813827
Transpl Int. 2012 Apr;25(4):464-70
pubmed: 22364312
Nephrol Dial Transplant. 2009 Sep;24(9):2780-5
pubmed: 19318356
J Hypertens. 2005 Oct;23(10):1905-11
pubmed: 16148615
Am J Transplant. 2005 Sep;5(9):2281-8
pubmed: 16095510
Radiol Med. 2005 Apr;109(4):385-94
pubmed: 15883523
Nephrol Dial Transplant. 2020 Sep 1;35(9):1577-1584
pubmed: 31028403
Br J Radiol. 1993 Jun;66(786):510-3
pubmed: 8330135
N Engl J Med. 2013 Nov 7;369(19):1797-806
pubmed: 24195547
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1181-1189
pubmed: 28242844
Transplantation. 2002 Jun 27;73(12):1923-8
pubmed: 12131689
Cardiovasc Ultrasound. 2014 Feb 20;12:9
pubmed: 24555729
J Hum Hypertens. 2007 Apr;21(4):291-6
pubmed: 17252030
Crit Care. 2012 Nov 15;16(6):174
pubmed: 23171782
Nephrol Dial Transplant. 2006 Oct;21(10):2916-20
pubmed: 16891640
Nephrol Dial Transplant. 2012 Aug;27(8):3315-20
pubmed: 22290990
Arthritis Res Ther. 2017 Sep 18;19(1):206
pubmed: 28923086
Clin Exp Nephrol. 2017 Jun;21(3):359-366
pubmed: 27530995
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Nephrol Dial Transplant. 2007 Jan;22(1):163-70
pubmed: 16936334

Auteurs

Jean-Baptiste de Freminville (JB)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France. jean.de-freminville@polytechnique.org.
University of Tours, Tours, France. jean.de-freminville@polytechnique.org.

Louis-Marie Vernier (LM)

Néphrologie-Dialyse, Centre de santé pluridisciplinaire, Le Mans, France.

Jérome Roumy (J)

Imagerie Médicale, Hôpital Bretonneau, CHU Tours, Tours, France.
CIC-IT 1415, CHU Tours, Tours, France.

Frédéric Patat (F)

University of Tours, Tours, France.
Imagerie Médicale, Hôpital Bretonneau, CHU Tours, Tours, France.
CIC-IT 1415, CHU Tours, Tours, France.

Philippe Gatault (P)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France.
University of Tours, Tours, France.
EA4245, University of Tours, Tours, France.

Bénédicte Sautenet (B)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France.
University of Tours, Tours, France.

Christelle Barbet (C)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France.

Hélène Longuet (H)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France.

Elodie Merieau (E)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France.

Matthias Buchler (M)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France.
University of Tours, Tours, France.
EA4245, University of Tours, Tours, France.

Jean-Michel Halimi (JM)

Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France.
University of Tours, Tours, France.
EA4245, University of Tours, Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH